EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy

Amanda Eckstrom, Anudishi Tyagi, Sajid Mahmood, Lilly Wong, Bahram Valamehr, Adishwar Rao iD, Akriti Agrawal, Maryam Siddiqui, V Lokesh Battula iD

Journal of Cellular and Molecular Medicine · 2025-01 · 29 (1)

DOI: 10.1111/jcmm.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 11.01.2025. Verfasst von Amanda Eckstrom und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Leukemia, Myeloid, Acute, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Fate Therapeutics, Inc., National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Induced pluripotent stem cell (iPSC)–derived natural killer (NK) cells offer an opportunity for a standardized, off‐the‐shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC‐NKs express a high‐affinity, noncleavable CD16 to maximize antibody dependent cellular cytotoxicity, a CD38 knockout to improve metabolic fitness, and an IL‐15/IL‐15 receptor fusion preventing the need for cytokine administration, the main source of adverse effects in NK cell–based therapies. Here, we sought to evaluate the potential of FT538 iPSC‐NKs as a therapy for AML through their effect on AML cell lines and primary AML cells. We observed that FT538 iPSC‐NKs induce effector‐to‐target cell ratio dependent apoptosis in cell lines and primary AML cells, including cells from high‐risk patients. Flow cytometric analysis revealed that FT538 iPSC‐NKs induce AML cell death when combined with the AML therapies: cytarabine, venetoclax and gilteritinib. Moreover, cytarabine did not affect FT538 iPSC‐NK viability, suggesting that iPSC‐derived NK therapies and chemotherapy may be a promising treatment combination. This study provides the basis for further study of iPSC‐derived NK cell therapies as a treatment option for high‐risk AML patients, particularly those with disease resistant to standard therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalLeukemia, Myeloid, AcuteInduced Pluripotent Stem CellsHumansCell Line, TumorApoptosisCytarabineBridged Bicyclo Compounds, HeterocyclicSulfonamidesCytotoxicity, Immunologic

Stichwörter der Autor:innen

AMLNK cell therapyNK cell‐mediated apoptosisiPSC‐derived NK cellsimmunotherapy

Substanzen

CytarabinevenetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fate Therapeutics, Inc., San Diego, California, USA.
  • Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Adishwar Rao, V Lokesh Battula

Förderung

  • NCI NIH HHS
  • Fate Therapeutics, Inc.
  • National Cancer Institute

Zitieren

APA

Eckstrom, A., Tyagi, A., Mahmood, S., Wong, L., Valamehr, B., Rao, A., Agrawal, A., Siddiqui, M., & Battula, V. L. (2025). FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy. Journal of Cellular and Molecular Medicine, 29(1). https://doi.org/10.1111/jcmm.70169

Vancouver

Eckstrom A, Tyagi A, Mahmood S, Wong L, Valamehr B, Rao A, et al. FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy. Journal of Cellular and Molecular Medicine. 2025;29(1). doi:10.1111/jcmm.70169

BibTeX
@article{Eckstrom2025,
  author = {Eckstrom, Amanda and Tyagi, Anudishi and Mahmood, Sajid and Wong, Lilly and Valamehr, Bahram and Rao, Adishwar and Agrawal, Akriti and Siddiqui, Maryam and Battula, V Lokesh},
  title = {FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  volume = {29},
  number = {1},
  doi = {10.1111/jcmm.70169}
}
Kostenlos starten →